Enzon Pharmaceuticals Files 8-K: Material Agreement & Security Holder Updates
Ticker: ENZN · Form: 8-K · Filed: Sep 30, 2025 · CIK: 727510
Sentiment: neutral
Topics: material-agreement, security-holder-rights, financial-statements
Related Tickers: ENZ
TL;DR
Enzon Pharma (ENZ) filed an 8-K today detailing a major new agreement and changes affecting security holders. Big news coming.
AI Summary
Enzon Pharmaceuticals, Inc. filed an 8-K on September 30, 2025, reporting an entry into a material definitive agreement and modifications to the rights of security holders. The filing also includes financial statements and exhibits, indicating significant corporate actions or disclosures for the company.
Why It Matters
This 8-K filing signals a significant corporate event for Enzon Pharmaceuticals, potentially impacting its business operations, financial standing, or shareholder rights.
Risk Assessment
Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce significant changes and potential risks to a company's operations and value.
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 22-2372868 (identifier) — IRS Employer Identification Number
FAQ
What is the nature of the material definitive agreement entered into by Enzon Pharmaceuticals?
The filing indicates an 'Entry into a Material Definitive Agreement' but does not specify the details of the agreement within the provided text.
What specific modifications were made to the rights of Enzon Pharmaceuticals' security holders?
The filing lists 'Material Modifications to Rights of Security Holders' as an item, but the specific modifications are not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 30, 2025.
What is Enzon Pharmaceuticals, Inc.'s state of incorporation?
Enzon Pharmaceuticals, Inc. is incorporated in Delaware.
What type of information is included in this 8-K filing besides the material agreement?
The filing also includes 'Financial Statements and Exhibits'.
Filing Stats: 1,003 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2025-09-30 16:45:37
Filing Documents
- tm2527543d1_8k.htm (8-K) — 30KB
- tm2527543d1_ex4-1.htm (EX-4.1) — 15KB
- 0001104659-25-095078.txt ( ) — 206KB
- enzn-20250930.xsd (EX-101.SCH) — 3KB
- enzn-20250930_lab.xml (EX-101.LAB) — 33KB
- enzn-20250930_pre.xml (EX-101.PRE) — 22KB
- tm2527543d1_8k_htm.xml (XML) — 3KB
01
Item 1.01 Entry into a Material Definitive Agreement. On September 30, 2025, Enzon Pharmaceuticals, Inc. (the " Company ") entered into the Fifth Amendment to the Section 382 Rights Agreement (the " Fifth Amendment "), which amends the Section 382 Rights Agreement, dated as of August 14, 2020 (the " Rights Agreement "), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent. Effective as of June 2, 2021, the Company amended the Rights Agreement (the " First Amendment ") to extend the Final Expiration Date (as defined in the Rights Agreement) of the rights issued pursuant to the Rights Agreement from the close of business on August 13, 2021 to the close of business on June 2, 2024. Effective as of May 16, 2024, the Company amended the Rights Agreement (the " Second Amendment ") to extend the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on June 2, 2024 to the close of business on March 31, 2025. Effective as of March 31, 2025, the Company entered into the Third Amendment (the " Third Amendment ") to extend the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on March 31, 2025 to the close of business on June 30, 2026. On August 13, 2025, the Company entered into the Fourth Amendment, to amend the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on June 30, 2026 to the close of business on September 30, 2025. On September 30, 2025, the Company entered into the Fifth Amendment to amend the Final Expiration Date of the rights issued pursuant to the Rights Agreement from the close of business on September 30, 2025 to the close of business on December 31, 2025. Except for the adjustment to the Final Expiration Date, the Rights Agreement otherwise remains unmodified. The Fifth Amendment has been adopted because the Company's management believes that it is in the best inte
03
Item 3.03 Material Modification to Rights of Security Holders. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 4.1 Fifth Amendment to the Section 382 Rights Agreement, dated as of September 30, 2025, by and between Enzon Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: September 30, 2025 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary